Johan Hansson

1987–2022 年に発表

96
論文数
19,497
被引用数
78
h 指数
95
i10 指数

被引用数

Johan Hansson の年別被引用数1976 年: 被引用 1 件1988 年: 被引用 3 件1989 年: 被引用 3 件1990 年: 被引用 6 件1991 年: 被引用 19 件1992 年: 被引用 16 件1993 年: 被引用 14 件1994 年: 被引用 12 件1995 年: 被引用 8 件1996 年: 被引用 17 件1997 年: 被引用 22 件1998 年: 被引用 25 件1999 年: 被引用 34 件2000 年: 被引用 29 件2001 年: 被引用 27 件2002 年: 被引用 32 件2003 年: 被引用 55 件2004 年: 被引用 66 件2005 年: 被引用 78 件2006 年: 被引用 64 件2007 年: 被引用 80 件2008 年: 被引用 78 件2009 年: 被引用 147 件2010 年: 被引用 191 件2011 年: 被引用 216 件2012 年: 被引用 188 件2013 年: 被引用 251 件2014 年: 被引用 238 件2015 年: 被引用 270 件2016 年: 被引用 288 件2017 年: 被引用 280 件2018 年: 被引用 234 件2019 年: 被引用 646 件2020 年: 被引用 744 件2021 年: 被引用 659 件2022 年: 被引用 463 件2023 年: 被引用 324 件2024 年: 被引用 505 件2025 年: 被引用 173 件2026 年: 被引用 12 件1977〜1987 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,488 件、この内訳の 24.8%中国: 引用元論文 709 件、この内訳の 7.1%イギリス: 引用元論文 681 件、この内訳の 6.8%ドイツ: 引用元論文 623 件、この内訳の 6.2%イタリア: 引用元論文 572 件、この内訳の 5.7%オーストラリア: 引用元論文 493 件、この内訳の 4.9%フランス: 引用元論文 445 件、この内訳の 4.4%オランダ: 引用元論文 429 件、この内訳の 4.3%スウェーデン: 引用元論文 346 件、この内訳の 3.4%スペイン: 引用元論文 305 件、この内訳の 3%カナダ: 引用元論文 270 件、この内訳の 2.7%スイス: 引用元論文 232 件、この内訳の 2.3%
0%24.8%その他 24.4%

分野

  • Biochemistry, Genetics and Molecular Biology42.2%
  • Medicine40.6%
  • Immunology and Microbiology10%
  • Health Professions1.8%
  • Engineering1.5%
  • Neuroscience0.9%
  • その他3%

トピック

  • Melanoma and MAPK Pathways8.1%
  • Cutaneous Melanoma Detection and Management6.3%
  • Cancer Immunotherapy and Biomarkers5.7%
  • Immunotherapy and Immune Responses4%
  • CAR-T cell therapy research2.9%
  • Immune cells in cancer2.6%
  • その他70.4%

共著者

全論文

検索で開く
  1. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 被引用: 1,871

  2. Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma

    著者: , , , , - Cancer Research 2018 被引用: 368

  3. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Winan J. van Houdt, Daniel S. Peeper, Andrew J. Spillane, Johan Hansson, Ton N. Schumacher, Georgina V. Long, Christian U. Blank - The Lancet Oncology 2019 被引用: 522

  4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 被引用: 1,386

  5. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa Elefanti, Siranoush Manoukian, Licia Rivoltini, Blair H. Smith, Maria A. Loizidou, Laura Del Regno, Daniela Massi, Mario Mandalà, Kiarash Khosrotehrani, Lars A. Akslen, Christopher I. Amos, Per Arne Andresen, Marie‐Françoise Avril, Esther Azizi, H. Peter Soyer, Véronique Bataille, Bruna Dalmasso, Lisa Bowdler, Kathryn P. Burdon, Wei V. Chen, Veryan Codd, Jamie E. Craig, Tadeusz Dębniak, Mario Falchi, Shenying Fang, Eitan Friedman, Sarah Simi, Pilar Galán, Zaida García‐Casado, Elizabeth M. Gillanders, Scott D. Gordon, Adèle C. Green, Nelleke A. Gruis, Johan Hansson, Mark Harland, Jessica Harris, Per Helsing, Anjali K. Henders, Marko Hočevar, Veronica Höiom, David J. Hunter, Christian Ingvar, Rajiv Kumar, Julie Lang, G.M. Lathrop, Jeffrey E. Lee, Xin Li, Jan Lubiński, Rona M. MacKie, M. Malt, Josep Malvehy, Kerrie McAloney, Hamida Mohamdi, Anders Molven, Eric K. Moses, Rachel Ε. Neale, Srdjan Novaković, Dale R. Nyholt, Håkan Olsson, Nick Orr, Lars G. Fritsche, Joan Anton Puig‐Butille, Abrar A. Qureshi, Graham Radford‐Smith, Juliette A. Randerson‐Moor, Celia Requena, Casey Rowe, Nilesh J. Samani, Marianna Sanna, Dirk Schadendorf ほか 59 名 - Nature Genetics 2020 被引用: 239

  6. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

    著者: , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2017 被引用: 284

  7. Skin cancer identification using multifrequency electrical impedance-a potential screening tool

    著者: , , , , , - IEEE Transactions on Biomedical Engineering, IEEE Trans. Biomed. Eng. 2004 被引用: 300

  8. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

    著者: , , , , , , , , , , , - Oncotarget 2017 被引用: 142

  9. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

    著者: , , , , , , , , , , , - Journal of Translational Medicine 2011 被引用: 531

  10. Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma

    著者: , , , , , , , , , , , , , - Scientific Reports 2019 被引用: 81

  11. Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling

    著者: , , , - Journal of Biological Chemistry 2003 被引用: 500

  12. Suffering in silence: a qualitative study of second victims of adverse events

    著者: , , , , - BMJ Quality & Safety 2013 被引用: 337

  13. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julia Newton‐Bishop, Jane M. Palmer, Susana Puig, Joan A. Puig‐Butille, Mitchell Stark, Hensin Tsao, M. A. Tucker, Linda Whitaker, Emanuel Yakobson - Journal of Medical Genetics 2006 被引用: 475

  14. Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms

    著者: , , , , , , , , , - Cancer Research 2013 被引用: 186

  15. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

    著者: , , , , , , , , , , , , , , , , , , , - OncoImmunology 2020 被引用: 50

  16. Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T cell‐and natural killer cell‐mediated cytotoxicity

    著者: , , , , , , , , - European Journal of Immunology 1996 被引用: 361

  17. Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production

    著者: , , , , , , , - Cancer Immunology Research 2013 被引用: 138

  18. FBXW7/hCDC4 Is a General Tumor Suppressor in Human Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2007 被引用: 519

  19. High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jane M. Palmer, Susana Puig, Joan A. Puig‐Butille, Femke A. de Snoo, Mitchell Stark, Hensin Tsao, Margaret A. Tucker, Linda Whitaker, Emanuel Yakobson, The Lund Melanoma Study Group - Cancer Research 2006 被引用: 418

  20. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eduardo Nagore, Rajiv Kumar, Johan Hansson, Jón Ólafsson, Jeffrey R. Gulcher, Augustine Kong, Unnur Þorsteinsdóttir, Kāri Stefánsson - Nature Genetics 2008 被引用: 355

  21. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases

    著者: , , , , - British Journal of Cancer 2013 被引用: 171

  22. Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

    著者: , , , , - Cancer Research 2010 被引用: 377

  23. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

    著者: , , , , , , , , , , , , , - Molecular Cancer Therapeutics 2008 被引用: 293

  24. Genome-wide association study identifies three loci associated with melanoma risk

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rona M. MacKie, Josep Malvehy, Graham J. Mann, Nicholas G. Martin, Grant W. Montgomery, Frans A. van Nieuwpoort, Srdjan Novaković, Håkan Olsson, Susana Puig, Marjan M. Weiss, Wilbert van Workum, Diana Zélénika, Kevin M Brown, Alisa M. Goldstein, Elizabeth M. Gillanders, Anne Boland, Pilar Galán, David E. Elder, Nelleke A. Gruis, Nicholas K. Hayward, G.M. Lathrop, Jennifer H. Barrett, Julia Newton‐Bishop - Nature Genetics 2009 被引用: 464